Paradigm Clinical Expands to Boise, Growing Therapeutic Expertise
February 8, 2024 – Paradigm Clinical Research, a leading clinical research site business, announces the opening of its latest clinical research site in Boise, Idaho. This marks a significant milestone as the company establishes its first site in Idaho, further advancing its footprint and its portfolio of therapeutic areas including women’s health studies. This emphasizes Paradigm Clinical Research’s commitment to making meaningful differences in the lives of the individuals and communities the company serves. The Boise site complements the company’s existing locations, reinforcing Paradigm Clinical Research’s dedication to establishing purpose-built research sites that cater to the growing demand for study participants and the crucial need for diverse populations and investigators. The expansion in Boise includes the company’s growing roster of partner investigators, including Dr. Keri Erland, Dr. Kelly Siudzinski, Dr. Tara Erbele, and Dr. Roger Wyatt, all playing pivotal roles in bringing clinical trial opportunities to the greater Treasure Valley community. Kurt Mussina, CEO of Paradigm Clinical Research, emphasized the unique aspect of this expansion, stating, “Boise represents more than a geographic extension for us; it’s an opportunity to make further strides in women’s health and our other therapeutic areas of interest. We are not merely opening a new location; we are expanding our commitment to advancing healthcare, particularly in areas that matter most to the community.” Paradigm Clinical Research’s newest clinical research site is located at 959 S. Allante Place, Boise, ID, 83709. Get Directions to Paradigm Clinical Research in Boise, ID Learn more about participating in a clinical study or becoming a principal investigator.
Paradigm Clinical Research Announces Expansion of Site Locations
Company Doubles Commitment in Denver Market with Additional Clinical Research Site REDDING, California; April 18, 2023 – Paradigm Clinical Research, a leading clinical research site business, announces the opening of its clinical research site in Littleton, Colorado, the company’s fourth location. The new site location complements the company’s long-standing site in Wheat Ridge, Colorado. This expansion is a continuation of Paradigm Clinical Research’s growth strategy, which focuses on creating purpose-built research sites to fulfill the industry’s demand for study participants and the critical need for diverse populations and investigators. As part of this strategy, the company has partnered with Andy Fine, M.D., who will serve as a principal investigator (PI) in Littleton. Dr. Fine is a primary care physician at Colorado Primary Health Care, which is the leading primary care group in the area, serving a large and diverse patient base. “We are thrilled to expand Paradigm Clinical Research’s reach in the Denver market and are excited about our partnership with Dr. Fine and other physician specialists in the area. Our mission is to provide the communities we serve with opportunities to advance the human condition through participation in expertly conducted clinical trials,” said Kurt Mussina, CEO of Paradigm Clinical Research. “I became a principal investigator because I want to be at the forefront of medical advancements that can have a positive impact on patients and help advance health care globally. That’s why I chose to partner with Paradigm Clinical Research — their commitment to honesty, integrity, and communication aligns with my values and ensures that we can conduct research in a way that benefits both our patients and the larger medical community,” said Dr. Fine. Paradigm Clinical Research is currently seeking additional principal investigators in Littleton and has a reception Wednesday, May 17, at 5:30 p.m. at Hotel Teatro for local physicians in the Denver area who are interested in supporting industry-sponsored clinical trials. To learn more about Paradigm Clinical Research or to inquire about becoming a principal investigator, please contact us.
As Paradigm Clinical Research Expands, So Does the Executive Team
Redding, California – Oct. 6, 2022 — Paradigm Clinical Research, with three dedicated research sites in California and Colorado, announced it has grown its executive leadership team, bringing on board Travis Milnes as chief financial officer (CFO) and Amy Henderson as head of clinical operations. These industry veterans provide additional leadership to Paradigm Clinical Research as the company executes on its plans to expand as a dedicated clinical research business covering a range of therapeutic areas for the biopharmaceutical industry. Travis Milnes, CPA, CFO, is focused on corporate strategy, finance, tax, treasury, information technology, human resources and contracts for Paradigm Clinical Research. He has extensive experience building teams and companies. Previously, at Advarra, Inc., he led the finance department through 11 acquisitions and integrations and four change-of-control transactions and was instrumental in the integration and implementation of standardized processes and procedures for an internationally dispersed team. He began his career as an audit manager with SB & Company, LLC. Amy Henderson, CCRC, head of clinical operations, brings deep experience leading international clinical research teams in highly complex interventional trials. She joined Paradigm Clinical Research from Frenova, the contract clinical research services business of Fresenius Medical Care, where her leadership was instrumental in achieving record-setting productivity, revenue and profitability performance for both Frenova and its partner investigators. At Paradigm Clinical Research, she has an integral role ensuring patient enrollment goals and financial performance objectives are met, as well as growing and managing high-performing sites. Kurt Mussina, who was recently announced as Paradigm Clinical Research’s new CEO, said, “Amy and Travis bring impressive records of success to Paradigm Clinical Research’s executive leadership team. Their experience and subject matter expertise are instrumental to drive our expansion plans not only in terms of additional site locations, but also therapeutic areas and our relationships with principal investigators and the clinical research community in general. I look forward to work with Amy and Travis as we build upon Paradigm Clinical Research’s history of achievement to become a dominant player in the clinical research site market.” About Paradigm Clinical Research Paradigm Clinical Research operates dedicated clinical research facilities with principal investigators actively involved in medical practice and clinical research. Founded in 2009, the company offers clinical trial opportunities to patients and healthy volunteers and provides high-quality study data to the biopharmaceutical industry.
Kurt Mussina Joins Paradigm Clinical as CEO to Lead Strategic Growth
REDDING, Calif.; Sept. 27, 2022 — Paradigm Clinical Research (Paradigm) announced the appointment of Kurt Mussina as CEO. He will bring more than 30 years of international business success to the clinical research site company, including a record of leadership and achievement structuring and orchestrating global teams in the CRO, CDMO and clinical research site industries. Founded in 2009, Paradigm currently operates three dedicated research sites with two in California and one in Colorado. Paradigm partners with principal investigators who are practicing physicians in a wide variety of medical specialties to execute both healthy volunteer and patient studies. Paradigm has deep expertise that is continuing to grow and a track record of success in neurology, ENT, internal medicine, pulmonology, infectious disease and dermatology, as well as deep experience in vaccine studies. “As the clinical research site landscape evolves, Paradigm is uniquely positioned for growth to become a dominant player in the space,” said Mussina. “Our approach is strategically tailored to addressing the day-to-day demands on our partner investigators, allowing them to participate in clinical trials while also managing successful medical practices. We are intensely fixated on creating and delivering value for all our stakeholders, including partner investigators, study volunteers, sponsors, CROs and our employees. We pride ourselves on delivering as promised, and I look forward to building on Paradigm’s history of achievement.” Before Paradigm, Mussina was president of Frenova, the contract clinical research services company of Fresenius Medical Care (FMC), while also serving as senior vice president in the Global Medical Office of FMC. The business expanded significantly under his leadership to become a network of managed and associated sites, including more than 550 principal investigators across 350 research sites in the U.S. He also led Frenova’s global expansion, leveraging an international network that included over 1,300 clinicians in 45 countries. Paradigm is backed by the private equity firm Crane Street Capital. Managing partner at Crane Street Capital Aleem Choudhry said, “Mussina has decades of experience and leadership with a passion for moving drug development, thus patient care, forward. This will not only help Paradigm to continue growing as a dedicated research business for a wide range of trials for the pharmaceutical industry, but his expertise will also continue to advance clinical research.” About Paradigm Clinical Research Paradigm Clinical Research operates dedicated clinical research facilities with principal investigators actively involved in medical practice and clinical research. Founded in 2009, the company offers clinical trial opportunities to patients and healthy volunteers and provides high-quality study data to the biopharmaceutical industry. About Crane Street Capital Group Crane Street Capital Group specializes in micro growth buyouts in a few selected fragmented industries with untapped white space potential for growth. Its investments target companies that not only have outsized growth potential within their industries but also have the ability to make tremendously positive impacts within the communities in which they operate. Crane Street maintains a concentrated portfolio, deploys capital on an independent basis when outstanding opportunities are available and implements a patient approach in value creation over typically 5+-year holding periods. Currently, there are six companies in the portfolio, three of which are in education services and three of which are in healthcare services.